In order to pursue a global cannabidiol (CBD) hemp market LiveWell Canada will transition its public shares to a different exchange.
Shares of LiveWell have been listed on the CSE under the same ticker symbol starting on Monday and will delist from the TMX Group exchange “in the near future.”
This move is due to the restrictions the TMX Group regulators have put in place for businesses with intentions in the contentious US market.
The Quebec-based company is looking to make a play in the US market with hemp-derived CBD products for wellness consumers.
“With the CSE listing, LiveWell is now positioned to pursue CBD opportunities not only in Canada, but globally… Listing on the CSE versus the TSXV allows us to take advantage of that,” David Rendimonti, president and CEO of LiveWell, said.
Shares of LiveWell on the TSXV dropped 1.20 percent in value near the end of the trading session on Monday, and reached a price of C$0.82.
The CSE has elected to not block listings to pursue business operations in the fractured US cannabis market despite the overall federal status of the drug.
Unlike its exchange competitors in Canada, the CSE has approved and encouraged the listing of several US-focussed cannabis or related companies.
During a panel at the Arcview Investor Forum in Las Vegas in mid-November, Richard Carleton, CEO of the CSE, told the audience the exchange had 52 US-related cannabis listings.
The executive added the exchange has raised C$1.5 billion for US cannabis companies throughout the year to the month of October, a figure he clarified was constantly changing with new listings.
“The CSE embraces transforming companies like LiveWell who are growing beyond the Canadian borders,” Rendimonti added.
LiveWell is banking on the potential for the CBD market in the US following the approval of the Hemp Farming Act of 2018.
This legislation introduced by Senate Majority Leader Mitch McConnell (R-KY) seeks to remove hemp from the controlled substances list as a Schedule I drug.
“Younger farmers in my state are particularly interested in going in this direction. We have a lot of people in my state who are extremely enthusiastic about the possibilities. As we all know, hemp is very diversified,” McConnell said in a CNBC report.
LiveWell shared with investors data from the Brightfield Group of Chicago currently estimates the North American CBD from hemp market may be worth US$22 billion by 2022.
The move to ditch the TSXV exchange in favor of a more welcoming one to US assets isn’t a new one.
This was done as the company wanted to retain its Nevada assets.
Dale Shirley, investor relations for Maple Leaf Green World, told the Investing News Network (INN) at the time, the US side of the company was “a big piece of the company” and divesting it was not an option.
“As a company deeply entrenched in the North American cannabis sector, it was important for management of the Company to select to partner with an exchange that has clear views on where it stands in relation to the industry,” Maple Leaf told investors.
In a statement at the time, the TMX Group said it asked its applicants and existing issuers to follow its requirements issued in a notice in October 2017.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.